منابع مشابه
An interview with Mark G. Hans
It is a great honor to conduct an interview with Professor Mark G. Hans, after following his outstanding work ahead of the Bolton-Brush Growth Study Center and the Department of Orthodontics at the prestigious Case Western Reserve School of Dental Medicine (CWRU) in Cleveland, Ohio. Born in Berea, Ohio, Professor Mark Hans attended Yale University in New Haven, CT, and earned his Bachelor of Sc...
متن کاملIrrepressible: An Interview with Mark Ptashne
While winter storms crippled almost every state fromWisconsin to Florida, our own force of nature blew into California in January in the compact human form of Mark Ptashne (Fig 1). Mark, who holds the Ludwig Chair of Molecular Biology at Sloan-Kettering in New York, had arrived to give a series of seminars on the West Coast. And if that weren’t enough, he also came prepared for a soirée, with h...
متن کاملSeizing the White Space: an interview with Mark W. Johnson
What makes opportunities like these so difficult to grasp is that, so often, they require companies to move far beyond their core into uncharted territory – into their white space. That’s a scary place, one where many companies’ experience is (as one CEO put it) “unblemished by success.” But if the danger is all too obvious, its causes are not. The white space is hard to navigate not because it...
متن کاملCTLA4, T cell function, and long term immunity: an interview with Dr. Mark K. Slifka. Interview by Helene F. Rosenberg.
Cytotoxic T lymphocyte antigen-4 (CTLA-4/CD152) is a member of the CD28 family of T cell effector antigens. Current belief, based primarily on results from gene-deleted mice, is that CTLA-4 promotes suppression of T cell proliferation. In this manuscript, Mark Slifka and colleagues compare antiviral responses of unmanipulated virus-specific CTLA-4 and CTLA-4 T cells. The results of this work su...
متن کاملInterview with Dr. Mark Cockett: Current Trends in Screening for Antiviral Therapeutics
Dr. Mark Cockett is Vice President of Infectious Diseases and Applied Genomics at Bristol-Myers Squibb (BMS). In this interview, we ask Dr. Cockett about considerations that major pharmaceutical companies such as BMS make when screening for and developing antiviral small molecule therapeutics. We discuss the rationale behind an unbiased screening approach that led to recent published work ident...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: AmeriQuests
سال: 2012
ISSN: 1553-4316
DOI: 10.15695/amqst.v9i1-2.3654